Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

October 13, 2017 updated by: GlaxoSmithKline

Observational Sutdy to Assess the Effectiveness of Avodart in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

173

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Birmingham, United Kingdom, B15 2TH
        • GSK Investigational Site
      • Bradford, United Kingdom, BD9 6RJ
        • GSK Investigational Site
      • Bradford, United Kingdom, BD5 0NA
        • GSK Investigational Site
      • Bristol, United Kingdom, BS2 8HW
        • GSK Investigational Site
      • East Kilbride, United Kingdom, G75 8RG
        • GSK Investigational Site
      • Hull, United Kingdom, HU16 5JD
        • GSK Investigational Site
      • Ilkeston, Derbyshire, United Kingdom, DE7 8LN
        • GSK Investigational Site
      • Leeds, United Kingdom, LS1 3EX
        • GSK Investigational Site
      • London, United Kingdom, EC1 7BE
        • GSK Investigational Site
      • London, United Kingdom, NW3 2QG
        • GSK Investigational Site
      • London, United Kingdom, W18 6BJ
        • GSK Investigational Site
      • Sheffield, United Kingdom, S10 2JF
        • GSK Investigational Site
      • Torquay, United Kingdom, TQ2 7AA
        • GSK Investigational Site
      • Wakefield, United Kingdom, WF1 4DG
        • GSK Investigational Site
    • Devon
      • Exeter, Devon, United Kingdom, EX2 5DW
        • GSK Investigational Site
      • Plymouth, Devon, United Kingdom, PL6 8DH
        • GSK Investigational Site
    • Essex
      • Colchester, Essex, United Kingdom, CO4 5JL
        • GSK Investigational Site
    • Hertfordshire
      • Stevenage, Hertfordshire, United Kingdom, SG2 4AB
        • GSK Investigational Site
    • Lancashire
      • Manchester, Lancashire, United Kingdom, M13 9WL
        • GSK Investigational Site
      • Manchester, Lancashire, United Kingdom, M8 5RB
        • GSK Investigational Site
    • Leicestershire
      • Leicester, Leicestershire, United Kingdom, LE5 4PW
        • GSK Investigational Site
    • London
      • Leytonstone, London, United Kingdom, E11 1NR
        • GSK Investigational Site
    • Middlesex
      • Enfield, Middlesex, United Kingdom, EN2 8JL
        • GSK Investigational Site
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
        • GSK Investigational Site
    • Somerset
      • Tauton, Somerset, United Kingdom, TA1 5DA
        • GSK Investigational Site
    • Tyne & Wear
      • Sunderland, Tyne & Wear, United Kingdom, SR4 7TP
        • GSK Investigational Site
    • West Midlands
      • Sutton Coldfield, West Midlands, United Kingdom, B75 7RR
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
  • Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
  • Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.

Exclusion criteria: None specified

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 25, 2004

Primary Completion (ACTUAL)

December 19, 2006

Study Completion (ACTUAL)

December 19, 2006

Study Registration Dates

First Submitted

April 20, 2006

First Submitted That Met QC Criteria

April 20, 2006

First Posted (ESTIMATE)

April 21, 2006

Study Record Updates

Last Update Posted (ACTUAL)

October 16, 2017

Last Update Submitted That Met QC Criteria

October 13, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 103500

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostatic Hyperplasia

Clinical Trials on IPSS Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe